FDA Licensed Capacity Avioq operates an FDA licensed manufacturing facility with ISO 13485:2016 certification and a history of FDA and ISO inspections, indicating reliability for regulated CDMO projects and potential for scale-up of diagnostic products.

Diversified HIV Assays A broad HIV portfolio including HIV-1, HIV-2, and HIV-1/Group M & O differentiation assays, plus an HTLV-I/II assay with CE marking and Health Canada approval, presenting multiple collaboration and licensing opportunities across blood screening and diagnostic markets.

End-to-End CDMO Avioq positions itself as a turnkey partner offering exploratory research through feasibility studies to manufacturing under a mature quality system, appealing to buyers seeking regulatory alignment and faster market entry.

Global Regulatory Footprint CE marking, Health Canada approval, and FDA licensing experience suggest strong regulatory credibility, enabling accelerated discussions with global customers needing compliant diagnostic solutions.

Growth and Partnerships With a mid-market revenue range and a niche focus in infectious disease diagnostics, Avioq can target mid-size biotech firms or larger CDMOs seeking specialized assay development, contract manufacturing, or regulatory support for blood donor and clinical testing workflows.